Trump’s Most-Favored-Nation pricing deal with Pfizer ignited the biggest two-day health care rally in five years. The agreement aligns Medicaid drug costs with the lowest prices in developed nations and includes discounts up to 80%, $70 billion in U.S. investments, and revenue repatriation. The White House is pressuring other drugmakers to strike similar deals under the threat of tariffs.